Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within inches of gaining Food and Drug Administration approvals and is turning its mind to an IPO.

Loading...

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.